Active	Status	Sponsor type	Region	Phase	Filter
3 Active 1 Inactive 4 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Nolè, Franco
JADE, NCT06256588: A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma	Recruiting	3	864	Europe, Canada, Japan, US, RoW	Dostarlimab, Placebo	GlaxoSmithKline	Neoplasms, Head and Neck	05/28	07/29
AxIn, NCT05817903 / 2022-001150-35: Axitinib Intensification Plus Nivolumab or Nivolumab Alone After Nivolumab Plus Ipilimumab in mRCC Patients	Recruiting	2	118	Europe	Axitinib, Inlyta, Nivolumab	Consorzio Oncotech, Pfizer	Metastatic Renal Cell Carcinoma	04/26	04/27